Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction

Heart Rhythm

Volumn 15, Issue 5, 2018, Pages 651-657

  Black Maier, Eric ^a   Ren, Xinru ^a   Steinberg, Benjamin A ^a   Green, Cynthia L ^a,b   Barnett, Adam S ^a   Rosa, Normita Sta ^a   Al Khatib, Sana M ^a,b   Atwater, Brett D ^a,b   Daubert, James P ^a   Frazier Mills, Camille ^a   Grant, Augustus O ^a   Hegland, Donald D ^a   Jackson, Kevin P ^a   Jackson, Larry R ^a   Koontz, Jason I ^a   Lewis, Robert K ^a   Sun, Albert Y ^a   Thomas, Kevin L ^a,b   Bahnson, Tristam D ^a,b   Piccini, Jonathan P ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Antiarrhythmic; Atrial fibrillation; Catheter ablation; Comparative effectiveness; Heart failure; Quality of life

Indexed keywords

ANTIARRHYTHMIC AGENT;

AGED; ARTICLE; ATRIAL FIBRILLATION; BODY MASS; CATHETER ABLATION; CLINICAL OUTCOME; COHORT ANALYSIS; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAYO ATRIAL FIBRILLATION SYMPTOM INVENTORY; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENT DISEASE; RETROSPECTIVE STUDY; TRANSTHORACIC ECHOCARDIOGRAPHY; COMPLICATION; HEART FAILURE; HEART MUSCLE CONDUCTION SYSTEM; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; SYSTOLE; TREATMENT OUTCOME;

AGED; ATRIAL FIBRILLATION; CATHETER ABLATION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART CONDUCTION SYSTEM; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; SYSTOLE; TREATMENT OUTCOME;

EID: 85041560303     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2017.12.001     Document Type: Article

References (18)

1. January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–e76.
2. Calkins, H., Brugada, J., Packer, D.L., et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 4 (2007), 816–861.
3. Di Biase, L., Mohanty, P., Mohanty, S., Santangeli, P., Trivedi, C., Lakkireddy, D., Reddy, M., Jais, P., Themistoclakis, S., Dello Russo, A., Casella, M., Pelargonio, G., et al. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: results from the AATAC multicenter randomized trial. Circulation 133 (2016), 1637–1644.
4. Marrouche, N.F., Brachmann, J., CASTLE-AF Steering Committee. Catheter Ablation Versus Standard Conventional Treatment in Patients with Left Ventricular Dysfunction and Atrial Fibrillation (CASTLE-AF)—study design. Pacing Clin Electrophysiol 32 (2009), 987–994.
5. Bursi, F., Weston, S.A., Redfield, M.M., Jacobsen, S.J., Pakhomov, S., Nkomo, V.T., Meverden, R.A., Roger, V.L., Systolic and diastolic heart failure in the community. JAMA 296 (2006), 2209–2216.
6. Hunter, R.J., Berriman, T.J., Diab, I., et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 7 (2014), 31–38.
7. Wilton, S.B., Fundytus, A., Ghali, W.A., Veenhuyzen, G.D., Quinn, F.R., Mitchell, L.B., Hill, M.D., Faris, P., Exner, D.V., Meta-analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patients with versus without left ventricular systolic dysfunction. Am J Cardiol 106 (2010), 1284–1291.
8. Cha, Y.M., Wokhlu, A., Asirvatham, S.J., et al. Success of ablation for atrial fibrillation in isolated left ventricular diastolic dysfunction: a comparison to systolic dysfunction and normal ventricular function. Circ Arrhythm Electrophysiol 4 (2011), 724–732.
9. Machino-Ohtsuka, T., Seo, Y., et al. Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 62 (2013), 1857–1865.
10. Olsson, L.G., Swedberg, K., Ducharme, A., Granger, C.B., Michelson, E.L., McMurray, J.J., Puu, M., Yusuf, S., Pfeffer, M.A., Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47 (2006), 1997–2004.
11. Linssen, G.C., Rienstra, M., Jaarsma, T., Voors, A.A., van Gelder, I.C., Hillege, H.L., van Veldhuisen, D.J., Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 13 (2011), 1111–1120.
12. Melenovsky, V., Hwang, S.J., Redfield, M.M., Zakeri, R., Lin, G., Borlaug, B.A., Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circ Heart Fail 8 (2015), 295–303.
13. Mentz, R.J., Broderick, S., Shaw, L.K., Fiuzat, M., O'Connor, C.M., Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease). J Am Coll Cardiol 63 (2014), 251–258.
14. Epstein, L.J., Kristo, D., Strollo, P.J. Jr., et al. Clinical guideline for the evaluation, management, and long term care of obstructive sleep apnea in adults. J Clin Sleep Med 5 (2009), 263–276.
15. Desai, A.S., Lewis, E.F., Li, R., et al. Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 162 (2011), 966–972.e10.
16. Wokhlu, A., Monahan, K.H., Hodge, D.O., Asirvatham, S.J., Friedman, P.A., Munger, T.M., Bradley, D.J., Bluhm, C.M., Haroldson, J.M., Packer, D.L., Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J Am Coll Cardiol 55 (2010), 2308–2316.
17. Vaduganathan, M., Michel, A., Hall, K., Mulligan, C., Nodari, S., Shah, S.J., Senni, M., Triggiani, M., Butler, J., Gheorghiade, M., Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. Eur J Heart Fail 18 (2016), 54–65.
18. Zakeri, R., Borlaug, B.A., McNulty, S.E., Mohammed, S.F., Lewis, G.D., Semigran, M.J., Deswal, A., LeWinter, M., Hernandez, A.F., Braunwald, E., Redfield, M.M., Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail 7 (2014), 123–130.